Merck and Daiichi Sankyo said a Phase 3 study evaluating patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer who received prior EGFR tyrosine ...
Approximately 350 patients were enrolled in the study. These patients were randomized in a 2:1:1 ratio to inclisiran (n=174), ezetimibe (n=89) or placebo (n=87). The primary endpoints were the ...